Fmoc-β-苯乙烯基-Ala-OH | 159610-82-9

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: Fmoc-β-苯乙烯基-Ala-OH
• 中文别名: 芴甲氧羰基-L-苯乙烯丙氨酸
• 英文名称: (S)-2-(9-Fluorenylmethoxycarbonylamino)-5-phenyl-4-(E)-penten-1-oic-acid
• 英文别名: Fmoc-L-Styrylalanine；(E,2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-5-phenylpent-4-enoic acid
• CAS: 159610-82-9
• 化学式: C₂₆H₂₃NO₄
• mdl: MFCD01311748
• 分子量: 413.473
• InChiKey: ZFMHHKMOLFNMMV-DDVUFSRBSA-N

物化性质

• 熔点：
  141.7 °C
• 沸点：
  532.63°C (rough estimate)
• 密度：
  1.2217 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.153
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• WGK Germany：
  3
• 海关编码：
  29242990
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H320,H335

SDS

Name:	(S)-N-FMOC-Styrylalanine 95% (98% E.E.) Material Safety Data Sheet
Synonym:	(S)-N-(9-Fluorenylmethoxycarbonyl)-2-Amino-5-Phenyl-4-Pentenenoic Acid
CAS:	159610-82-9

Section 1 - Chemical Product MSDS Name:(S)-N-FMOC-Styrylalanine 95% (98% E.E.) Material Safety Data Sheet
Synonym:(S)-N-(9-Fluorenylmethoxycarbonyl)-2-Amino-5-Phenyl-4-Pentenenoic Acid

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
159610-82-9	(S)-N-FMOC-Styrylalanine	95%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 159610-82-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white to off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 141.7 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C26H23NO4
Molecular Weight: 413.48

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 159610-82-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(S)-N-FMOC-Styrylalanine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 159610-82-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 159610-82-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 159610-82-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  Fmoc-β-苯乙烯基-Ala-OH 在 N-乙基马来酰亚胺 作用下， 生成 [(S)-1-((E)-(S)-1-Carbamoyl-4-phenyl-but-3-enylcarbamoyl)-propyl]-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Dipeptidyl nitriles as human dipeptidyl peptidase I inhibitors

  摘要：

  Using a dipeptide nitrile scaffold we have identified a potent and selective inhibitor of human dipeptidyl peptidase I. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.102
• 作为产物：
  描述：

  氯甲酸-9-芴基甲酯 以 四氢呋喃 、 二氯甲烷 、 水 、 乙酸乙酯 为溶剂， 生成 Fmoc-β-苯乙烯基-Ala-OH
  参考文献：
  名称：

  Single chain peptide compounds having hemoregulatory activity

  摘要：

  披露了单链肽化合物，其在非末端氨基酸的C.alpha.-原子上被一个在权利要求1中定义的-A基团取代。C.alpha.原子的天然α侧链与基团-A缺失。根据本发明的肽衍生物可用于抑制细胞增殖，特别是骨髓和骨髓细胞。

  公开号：

  US05629293A1

文献信息

• Compounds That Inhibit Replication Of Human Immunodeficiency Virus
  申请人：Balzarini Maria Rene Jan

  公开号：US20080076824A1

  公开（公告）日：2008-03-27

  The present invention relates to the discovery of a novel class of compounds that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compounds. More specifically, it has been found that enzymatically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compounds that inhibit HUV, methods to isolate and synthesize modified glycinamide compounds, and therapeutic compositions comprising these compounds.

  本发明涉及一种新型化合物类别的发现，该类化合物能够抑制人类免疫缺陷病毒（HIV）的复制，并提供了鉴定这些化合物的方法。具体来说，发现经酶法制备的α-羟基甘氨酰胺和人工合成的α-羟基甘氨酰胺能够抑制HIV在人血清中的复制。实施例包括鉴定抑制HUV的改性甘氨酰胺化合物的方法，分离和合成改性甘氨酰胺化合物的方法，以及包含这些化合物的治疗组合物。
• C-Terminal Modifications of Apelin-13 Significantly Change Ligand Binding, Receptor Signaling, and Hypotensive Action
  作者：Alexandre Murza、Élie Besserer-Offroy、Jérôme Côté、Patrick Bérubé、Jean-Michel Longpré、Robert Dumaine、Olivier Lesur、Mannix Auger-Messier、Richard Leduc、Philippe Sarret、Éric Marsault

  DOI：10.1021/jm501916k

  日期：2015.3.12

  Apelin is the endogenous ligand of the APJ receptor, a member of the G protein-coupled receptor family. This system plays an important role in the regulation of blood pressure and cardiovascular functions. To better understand the role of its C-terminal Phe13 residue on ligand binding, receptor signaling, and hypotension, we report a series of modified analogues in which Phe13 was substituted by unnatural amino acids. These modifications delivered new compounds exhibiting higher affinity and potency to inhibit cAMP accumulation compared to apelin-13. In particular, analogues Bpa(13) or (alpha-Me)Phe(13) were 30-fold more potent to inhibit cAMP accumulation than apelin-13. Tyr(OBn)(13) substitution led to a 60-fold improvement in binding affinity and induced stronger and more sustained drop in blood pressure compared to apelin-13. Our study identified new potent analogues of apelin-13, which represent valuable probes to better understand its structurefunction relationship.
• SINGLE CHAIN PEPTIDE COMPOUNDS HAVING HEMOREGULATORY ACTIVITY
  申请人：Hafslund Nycomed AS

  公开号：EP0643725A1

  公开（公告）日：1995-03-22
• SPECIFIC INHIBITORS AND ACTIVE SITE PROBES FOR LEGUMAIN
  申请人：Lee Jiyoun

  公开号：US20120251459A1

  公开（公告）日：2012-10-04

  Compounds which specifically inhibit legumain, also known as asparaginyl endopeptidase are provided. The compounds have an epoxide or N-Michael acceptor warhead, and have an asparagine side chain attached to a nitrogen atom in the backbone adjacent the warhead. The compounds also preferably comprise a proline residue adjacent the asparagine, and the compound may also contain a third residue and/or a label for cellular or in vivo imaging of active legumain.
• US5629293A
  申请人：——

  公开号：US5629293A

  公开（公告）日：1997-05-13